Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2008-08-15 Board/Management Inform…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Board/Management Information 2008
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd. It reports receipt of a Nasdaq Staff Deficiency Letter regarding non-compliance with audit committee composition rules due to changes in board composition. The document discusses governance and compliance issues related to board and audit committee members but does not contain financial statements or detailed financial data. It is primarily an announcement about board composition and regulatory compliance. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2008-08-15 English
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd. It is dated August 14, 2008, and provides updated risk factors related to clinical trials and regulatory approvals. The document references the company's Annual Report on Form 20-F filed on March 27, 2008, but this document itself is not the annual report; rather, it is an update to risk factors disclosed in that annual report. Form 6-K filings are periodic reports submitted by foreign private issuers to provide information that is material to investors but does not constitute a full annual or interim report. The content is primarily narrative risk factor updates, not financial statements or earnings data. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2008-08-14 English
Board/Management Information 2008
Board/Management Information Classification · 100% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd. It announces the appointment of a new board member, Samuel H. Rudman, to the company's Board of Directors. The content focuses on management changes rather than financial results, audit information, or other report types. The document length is 5901 characters, which is sufficient to contain substantive information. The key phrase 'XTL Biopharmaceuticals Announces Appointment of Samuel H. Rudman to Board of Directors' clearly indicates a management change announcement. Therefore, the document fits the category of Board/Management Information (MANG).
2008-08-14 English
Interim / Quarterly Report 2008
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd., reporting its first half 2008 financial results. The text includes detailed financial data for the six months ended June 30, 2008, including statements of operations and balance sheet information. The document is not an annual report (10-K) or a quarterly report (10-Q) but a Form 6-K, which is used by foreign private issuers to report material information. The content includes substantive financial data and analysis for a period shorter than a full fiscal year (half-year). Therefore, this document fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification but contains actual financial statements and management commentary on the results. Hence, the appropriate classification is IR with high confidence.
2008-08-14 English
Report of Periodic or Interim Report
Regulatory Filings
2008-08-14 Hebrew (modern)
Report of Periodic or Interim Report
Report Publication Announcement Classification · 100% confidence The document is a short regulatory filing (1,725 characters) that serves as a cover sheet for a financial report. It explicitly states 'Attached hereto is a report on First Half 2008 Financial Results' and provides a filename for the attachment. Per the 'Menu vs Meal' rule, since this document is an announcement of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA). H1 2008
2008-08-14 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.